Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation regimen aims to cut prostate cancer treatment time

NCT ID NCT00809991

Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tested a radiation therapy plan that gives a slightly higher dose each day over fewer sessions (16 days instead of the usual 8-9 weeks) for men with early-stage prostate cancer. The goal was to see if this shorter schedule is safe and effective, while also tracking quality of life and side effects. 91 men with low-risk prostate cancer participated, and researchers measured urinary, bowel, and sexual function over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy (hypofractionated, image-guided)
What this could lead to
If successful, this could offer a more convenient and equally effective radiation schedule for men with early-stage prostate cancer.
What could go wrong
This is a small Phase 2 study, so results may not apply to all patients. The higher daily dose could increase side effects like urinary or bowel issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

91 people

The number who actually took part.

Started

Dec 2008

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed, locally confined adenocarcinoma of the prostate * Clinical stages T1a to T2b PSA of less than 10 ng per ml * Gleason score of less than 3+4=7 * The patient has decided to undergo external beam radiation as treatment choice for his prostate cancer * Signed study-specific consent form prior to registration Exclusion Criteria: * Stage T3 to 4 disease * Gleason 4+3=7 or higher score * PSA greater than 10 ng per ml * Clinical or Pathological Lymph node involvement N1 * Evidence of distant metastases M1 * Radical surgery for carcinoma of the prostate * Previous Chemotherapy or pelvic radiation therapy * Previous or concurrent cancers other than basal or squamous cell skin cancers or superficial bladder cancer unless disease free for at least 5 years * History of inflammatory bowel disease * Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized adenocarcinoma of the prostate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • The Johns Hopkins University School of Medicne

    Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.